Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 3Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 3Myeloid 1

Conditions

Myeloproliferative Disorders 1Lymphoma, Non-Hodgkin 1

Interventions

fludarabine 23Cyclophosphamide 23fludarabine phosphate 18Tacrolimus 16venetoclax 15ruxolitinib 15Melphalan 15Azacitidine 15Whole-Body Irradiation 12Mycophenolic Acid 12Cytarabine 11Busulfan 11Thiotepa 9Specimen Handling 9Decitabine 9Stem Cell Transplantation 8Granulocyte Colony-Stimulating Factor 8Biopsy 8Peripheral Blood Stem Cell Transplantation 7Imatinib Mesylate 7decitabine and cedazuridine drug combination 6Sirolimus 6Methotrexate 6Injections 6thymoglobulin 5nilotinib 5X-Rays 5Phantoms, Imaging 5Nuclear Medicine Department, Hospital 5Magnetic Resonance Spectroscopy 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × parsaclisib × Myeloid × Clear all
NCT04509700 2025-12-10

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Incyte Corporation

Phase 2 Active not recruiting
112 enrolled
LymphoidMyeloid

Lymphoma, Non-Hodgkin, Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡